Jazz rises on updated OS results from gastric cancer study
- Posted on September 1, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Jazz rises on updated OS results from gastric cancer study
Jazz Pharmaceuticals JAZZ announced second interim top-line overall survival (OS) results from the phase III HERIZON-GEA-01 study, which evaluated different combination regimens involving its marketed drug, Ziihera (zanidatamab) as a first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The HERIZON-GEA-01 study evaluated two regimens — Ziihera plus chemotherapy and Ziihera combined with BeOne...
